Improving the cost-effective evaluation and management of atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesions

Cancer

Volumn 84, Issue 1, 1998, Pages 1-4

  Horowitz, Ira R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA HYBRID;

CARCINOMA IN SITU; COLPOSCOPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CURETTAGE; CYTODIAGNOSIS; DNA HYBRIDIZATION; EDITORIAL; HEALTH CARE COST; PAPANICOLAOU TEST; PATIENT CARE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

EID: 0032564806     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980225)84:1<1::AID-CNCR1>3.0.CO;2-U     Document Type: Editorial

References (14)

1. Alanen KW, Elit LM, Molinaro PA, McLachlin CM. Assessment of cytologic follow-up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Cancer (Cancer Cytopathol) 1998;84:5-10.
2. Williams ML, Rimm DL, Pedigo MA, Frable WJ. Atypical squamous cells of undetermined significance: correlative histologic and follow-up studies from an academic medical center. Diagn Cytopathol 1997;16(1):1-7.
3. Gonzalez D, Hernandez E, Andersen L, Heller P, Atkinson BF. Clinical significance of a cervical cytologic diagnosis of atypical squamous cells of undetermined significance. Favoring a reactive process or low grade squamous intraepithelial lesion. J Reprod Med 1996;41(10):719-23.
4. Sheils LA, Wilbur DC. Atypical squamous cells of undetermined significance. Stratification of the risk of association with, or progression to, squamous intraepithelial lesions based on morphologic subcategorization. Acta Cytol 1997;41(4):1065-72.
5. Miguel NL Jr., Lachowicz CM, Kline TS. Candida-related changes and ASCUS: a potential trap. Diagn Cytopathol 1997;16(1):83-6.
6. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. 1992 National Cancer Institute Workshop: Interim Guidelines for Management of Abnormal Cervical Cytology. JAMA 1994;271(23):1866-9.
7. Kaufman RH. Atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion: diagnostic criteria and management. Am J Obstet Gynecol 1996;1975:1120-8.
8. Kennedy AW, Salmieri SS, Wirth SL, Biscotti CV, Tuason LJ, Travarca MJ. Results of the clinical evaluation of atypical glandular cells of undetermined significance (AGCUS) detected on cervical cytology screening. Gynecol Oncol 1996;63(1):14-8.
9. Sherman ME, Schiffman MH, Lorincz AT, Herrero R, Hutch- inson ML, Bratti C, et al. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer 1997;81(2):89-97.
10. Kaufman RH, Adam E, Icenogle J, Lawson H, Lee N, Reeves KO, et al. Relevance of human papillomavirus screening in management of cervical intraepithelial neoplasia. Am J Obstet Gynecol 1977;176(1):87-92.
11. Michelow PM, Hlongwane NF, Leiman G. Simulation of primary cervical cancer screening by the PAPNET system in an unscreened, high-risk community. Acta Cytol 1997;41(1):88-92.
12. Liao SY, Stanbridge EJ. Expression of the MN antigen in cervical papanicolaou smears is an early diagnostic biomarker of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 1996;5(7):549-57.
13. Boon ME, Kleinschmidt-Guy ED, Wijsman-Grootendorst A, Hoogeveen MM. Upgrading unsatisfactory cervical smears with the MIB-1 method. Diagn Cytopathol 1996;15(4):270-6.
14. Kurtycz D, Nunez M, Arts T, Bauman C, Harris C, Inhorn S, et al. Use of fluorescent in situ hybridization to detect aneuploidy in cervical dysplasia. Diagn Cytopathol 1996;15(1):46-51.